Last reviewed · How we verify
0.5% Bupivicaine
At a glance
| Generic name | 0.5% Bupivicaine |
|---|---|
| Also known as | Marcaine, Sensorcaine |
| Sponsor | Lahey Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- COMFORT Trial: Complex Obstetric Management With Focused Regional Transversus Abdominis Plane Block (PHASE4)
- Post Operative Infusion Pump Pain Study (PHASE4)
- Periarticular Injection Versus Popliteal Block (PHASE4)
- Dexmedetomidine as an Adjuvant to Bupivacaine for Ultrasound-Guided External Oblique Intercostal Block (NA)
- Exparel Versus Bupivacaine in Post-operative Pain Control (PHASE4)
- Comparison of Intrathecal Bupivacaine With and Without Morphine for Post-operative Analgesia in Parturients Undergoing Elective Cesarean Section: A Randomized Controlled Trial (PHASE4)
- Effectiveness of Per-Operative Bupivicaine in Reducing Postoperative Pain at Port Site and Improving Mobility in Knee Arthoscopic Procedures (PHASE4)
- Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.5% Bupivicaine CI brief — competitive landscape report
- 0.5% Bupivicaine updates RSS · CI watch RSS
- Lahey Clinic portfolio CI